Evidence map›Paper›PMID 42889415›Full record

ArticleFrontiers in immunology2026

Systemic immune activation coexists with compartment-specific regulatory enrichment in matched blood, peritumor, and tumor tissue from advanced oral squamous cell carcinoma.

Nayane Alves de Lima Galdino, Flávio Pignataro-Oshiro, João Figueira Scarini, Raísa Sales de Sá, Guilherme Ferreira de Britto Evangelista, Amanda Braga Figueiredo, Clara Maciel Cavalcanti, Katia Luciano Pereira Morais, Vanessa Alves Gasparini, Hugo Fontan Kohler and 3 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nayane Alves de Lima GaldinoTranslational Immuno-Oncology Group, International Research Center, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Flávio Pignataro-OshiroTranslational Immuno-Oncology Group, International Research Center, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
João Figueira ScariniTranslational Immuno-Oncology Laboratory, Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Raísa Sales de SáTranslational Immuno-Oncology Laboratory, Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Guilherme Ferreira de Britto EvangelistaTranslational Immuno-Oncology Group, International Research Center, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Amanda Braga FigueiredoTranslational Immuno-Oncology Group, International Research Center, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Clara Maciel CavalcantiCenter for Research in Immuno-Oncology (CRIO), Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Katia Luciano Pereira MoraisTranslational Immuno-Oncology Group, International Research Center, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Vanessa Alves GaspariniInternational Research Center, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Hugo Fontan KohlerMedical Oncology Department, Head and Neck Cancer Reference Center, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Thiago Bueno de OliveiraMedical Oncology Department, Head and Neck Cancer Reference Center, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Luiz Paulo KowalskiDepartment of Head and Neck Surgery and Otorhinolaryngology, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Kenneth J GollobTranslational Immuno-Oncology Group, International Research Center, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Oral squamous cell carcinoma (OSCC) is the most prevalent form of oral cancer and is characterized by a poor prognosis and frequent immune evasion. While the tumor microenvironment (TME) plays a central role in modulating responses to therapy, its relationship with systemic immune signatures remains poorly understood. Methods: We performed high-dimensional immune profiling in matched peripheral blood, adjacent non-neoplastic peritumor mucosa, and tumor tissue from Human Papillomavirus (HPV)-negative, treatment-naïve patients with advanced OSCC. Soluble mediators were quantified by multiplex immunoassay, and immune cell phenotypes were assessed by multiparametric flow cytometry. Compartment-specific patterns were evaluated using paired and unpaired comparisons, dimensionality reduction, ordinal trend analysis, unsupervised clustering, and correlation networks. Results: Seventeen plasma mediators were significantly elevated in OSCC patients compared with healthy donors. Paired cellular profiling identified compartment-specific differences across blood, peritumor and tumor, and selected PD-1 Conclusions: Advanced OSCC is associated with distinct systemic and tissue immune profiles. These exploratory findings identify compartment-specific immune features and selected monotonic trends that warrant future spatial, functional, and clinical validation.

Indexed as

Carcinoma, Squamous CellMouth NeoplasmsTumor MicroenvironmentAgedCytokinesFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedT-Lymphocytes, RegulatoryCytokinesadvanced OSCChigh-dimensional immune profilingimmune compartmentsimmune exhaustionMAIT-like cellsPD-1/PD-L1tumor microenvironment

Identifiers

PMID42889415
PMCPMC13669159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.